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Abstract
Multiple prostate cancer (PCa) risk-related loci have been discovered by genome-wide association
studies (GWAS) based on case–control designs. However, GWAS findings may be confounded by
population stratification if cases and controls are inadvertently drawn from different genetic
backgrounds. In addition, since these loci were identified in cases with predominantly sporadic
disease, little is known about their relationships with hereditary prostate cancer (HPC). The
association between seventeen reported PCa susceptibility loci was evaluated with a family-based
association test using 1,979 hereditary PCa families of European descent collected by members of
the International Consortium for Prostate Cancer Genetics, with a total of 5,730 affected men. The
risk alleles for 8 of the 17 loci were significantly over-transmitted from parents to affected
offspring, including SNPs residing in 8q24 (regions 1, 2 and 3), 10q11, 11q13, 17q12 (region 1),
17q24 and Xp11. In subgroup analyses, three loci, at 8q24 (regions 1 and 2) plus 17q12, were
significantly over-transmitted in hereditary PCa families with five or more affected members,
while loci at 3p12, 8q24 (region 2), 11q13, 17q12 (region 1), 17q24 and Xp11 were significantly
over-transmitted in HPC families with an average age of diagnosis at 65 years or less. Our results
indicate that at least a subset of PCa risk-related loci identified by case–control GWAS are also
associated with disease risk in HPC families.
Introduction
Genome-wide association studies (GWAS) have succeeded in identifying low penetrance
genetic risk factors that account for differing proportions of the hereditary variance
associated with complex diseases (Manolio 2010). Using a GWAS approach, several
hundred thousand to more than a million single nucleotide polymorphisms (SNPs) are
assayed in thousands of individuals to compare the allele frequencies between the cases and
the controls for each SNP (Hardy and Singleton 2009). Cases are generally a set of
individuals who have been diagnosed with disease by a certain point in time, while controls
are unaffected as of a particular reference date. One or more additional case–control studies
are generally needed to confirm the GWAS findings, as the risk of false positives is
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appreciable. Although reproducibility in multiple independent study populations is a strong
argument for the existence of disease-associated SNPs, population stratification between
cases and controls due to population admixture or natural selective pressure resulting in
false-positive associations remains a concern (Price et al. 2010). In addition, it is critical to
know if variants identified by studies of individuals from the general population are
associated with disease risk among high-risk families.
Prostate cancer (PCa) has been extensively studied using GWAS, and the results have
identified and replicated multiple risk-related SNPs (Amundadottir et al. 2006; Duggan et al.
2007; Eeles et al. 2008; Gudmundsson et al. 2007a, b; Thomas et al. 2008; Yeager et al.
2007). However, most of these variants were identified in case–control datasets in which
there may have been the possibility of population stratification. Thus, it is of interest to
further assess these findings in family-based studies. In addition, subjects participating in the
reported case–control studies were generally recruited from the general population, and thus
primarily represent sporadic cancer cases. Although familial cases have been included in
some GWAS studies (Eeles et al. 2008), less is known about the relative importance of most
of the risk alleles in high-risk or hereditary prostate cancer (HPC) families. In the present
study, we sought to assess whether the genetic markers identified by GWAS are also
relevant for HPC families. To address this question, we conducted a large family-based
association study that included 1,979 Caucasian HPC families collected by members of the
International Consortium for Prostate Cancer Genetics (ICPCG) to evaluate 17 loci that
demonstrated a previous association with PCa in GWAS.
Subjects and methods
Study population
The ICPCG study population has been described in detail previously (Schaid and Chang
2005; Xu et al. 2005). Twelve groups participated in the present study, including ACTANE
(Anglo/Canadian/Texan/Australian/Norwegian/European Union Biomed), BC/CA/HI
(British Columbia, California, Hawaii), CeRePP (Centre de Recherche pour les Pathologies
Prostatiques), Fred Hutchinson Cancer Research Center/National Human Genome Research
Institute (FHCRC/NHGRI), Johns Hopkins University (JHU), Mayo Clinic, Northwestern
University, University of Michigan, University of Tampere in Finland, University of Ulm in
Germany, University of Umeå in Sweden, and University of Utah.
Each group within the ICPCG recruited its population via different methods of pedigree
ascertainment and confirmation of PCa diagnosis (Schaid and Chang 2005). Nevertheless,
there was a general consensus that affected individuals were all defined as men affected with
PCa that had been confirmed by either medical records or death certificates. The status of
self- or relative-reported men without either medical records or death certificate
confirmation was considered as “unknown”. In addition, the affection status of all men
without a diagnosis of PCa was coded as “unknown”, regardless of whether they had
undergone screening for PCa. Hence, all analyses were based on the sharing of marker
genotypes among affected men, with no consideration of phenotype for the remaining
subjects. In total, 2,068 PCa families were collected by the ICPCG. After 89 families with
African, Asian or other non-Caucasian ancestry (56, 15 and 18 families, respectively) were
excluded from these analyses, the remaining 1,979 families with Caucasian ancestry were
included in this study (Table 1). These families included a total of 5,730 affected members.
Research protocols and study documentation were approved by each group’s Institutional
Review Board.
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One SNP was selected from each of the 17 loci that had been shown to be significantly
associated with PCa risk in previous GWAS (P < 10−8) (Amundadottir et al. 2006; Duggan
et al. 2007; Eeles et al. 2008; Gudmundsson et al. 2007a, b; Thomas et al. 2008; Yeager et
al. 2007) and subsequently in a follow-up fine-mapping study (Sun et al. 2008b). As shown
in Table 2, the loci included three independent positions at 8q24, two at 17q12, and one SNP
each at chromosome 2p15, 3p12, 6q25, 7p15, 7p21, 9p13, 10q11, 10q26, 11q13, 17q24,
19q13, and Xp11. Moreover, seven additional SNPs at three independent regions of 8q24
(Witte 2007) were also included: two from region 1, three from region 2 and two from
region 3. In addition, we included one SNP (rs979200) that was centromeric to the three at
8q24 that was found to be associated with PCa risk in fine-mapping studies (Salinas et al.
2008; Sun et al. 2008a).
Genotyping
All samples were coordinated and genotyped using the MassARRAY iPLEX (Sequenom,
Inc., San Diego, CA, USA) at the Center for Cancer Genomics, Wake Forest University.
Briefly, PCR assays were performed in a total volume of 5 μL that contained 10 ng of
genomic DNA, 3.5 mM of MgCl2, 0.5 U of HotStarTaq polymerase (QIA-GEN Inc.,
Valencia, CA, USA), 0.5 mM of each dNTP (Invitrogen, Carlsbad, CA, USA), and 0.06 μM
of each primer. The PCR cycling conditions were 94°C for 15 min; followed by 45 cycles of
94°C for 20 s, 56°C for 30 s, and 72°C for 1 min; followed by a final extension at 72°C for 3
min. Shrimp alkaline phosphatase (SAP) treatments were performed in a total volume of 7
μL that contained the entire PCR mixture and 0.3 U of SAP, with incubation at 37°C for 40
min. The iPLEX extension reactions were performed in a total volume of 9 μL that included
the entire SAP reaction and 1× iPLEX termination mix, 1× iPLEX enzyme, and 5.625 μM
of each extension primer. The samples were desalted with 6 mg of clean resin and then
dispensed to a SpectroCHIP. The chips were scanned using the MALDI-TOF MS system,
and the genotypes were analyzed by the MassARRAY Typer 3.4 (Sequenom Inc.).
Duplicates and negative controls were included in each 96-well plate to ensure quality
control (QC). Genotyping was performed by technicians blinded to sample status. The
average concordance rate was >98% for the 25 SNPs.
Statistical methods
To test the linkage or linkage disequilibrium (association) of genotypes with HPC, data from
nuclear families and (or) sibships were used to perform a family-based association test
(FBAT). FBAT evaluates whether particular alleles are transmitted from parents to affected
offspring in a proportion that is different from that expected under the null hypothesis of no
association between marker and disease. The empirical variance estimator in FBAT was
used to perform a valid test of association, accounting for the correlation of transmitted
alleles among multiple affected individuals in the same family due to coinheritance. FBAT
analysis was carried out using the appropriate software (Laird et al. 2000).
Results
The characteristics of the 1,979 ICPCG Caucasian HPC families are summarized in Table 1.
More than 15% of families (305/1,979) had five or more members affected with PCa.
Among 1,690 families with available information on age at prostate cancer diagnosis, 796
families (47.1%) had an average age at diagnosis ≤65 years.
As shown in Table 2, 7 of the 17 loci that were originally associated with PCa risk in
previous GWAS showed a statistically significant association based on the family-based
association tests. These included 8q24 region 2 (rs16901979, P = 0.031), 8q24 region 3
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(rs6983267, P = 0.017), 10q11 (rs10993994, P = 6.70 × 10−5), 11q13 (rs10896449, P = 2.31
× 10−3), 17q12 region 1 (rs4430796, P = 0.010), 17q24 (rs1859962, P = 1.03 × 10−4) and
Xp11 (rs5945619, P = 6.92 × 10−4). Among eight additional SNPs selected at 8q24, three
regions demonstrated one significant SNP each (region 1: rs4242382, P = 0.011; region 2:
rs1016343, P = 0.020; and region 3: rs7837328, P = 0.019). For all of the significant SNPs,
the direction of association was consistent with the original reports, i.e., the over-transmitted
alleles from parents to affected men (S-E(S) >0) were the same as the risk alleles reported in
the original studies (Amundadottir et al. 2006; Duggan et al. 2007; Eeles et al. 2008;
Gudmundsson et al. 2007a, b; Thomas et al. 2008; Yeager et al. 2007).
To evaluate the role of these selected SNPs in subsets of families characterized by number
of affected individuals or early mean age at diagnosis, we performed an FBAT analysis,
specifically, in families with five or more affected men, or those with an average age at
diagnosis of 65 years or less. As shown in Table 3, among 305 families with five or more
affected individuals, previously reported risk alleles for five SNPs in three loci were
significantly over-transmitted from parents to affected men, including four SNPs found to be
significant in all families: 8q24 region 1 (rs4242382: P = 0.010), 8q24 region 2
(rs16901979: P = 0.034; and rs1016343: P = 0.010), and 17q24 (rs1859962: P = 1.62 ×
10−3), and one additional SNP at 8q24 region 1 (rs10091054: P = 0.045). For 796 families
with average age of diagnosis ≤65 years, the risk alleles for six SNPs were found to be
significantly over-transmitted, including five SNPs at 8q24 region 2 (rs16901979: P =
0.023), 11q13 (rs10896449: P = 0.010), 17q12 region 1 (rs4430796: P = 0.012), 17q24
(rs1859962: P = 8.01 × 10−4) and Xp11 (rs5945619: P = 4.70 × 10−3) that were also
observed to be significant in all families, and one additional SNP at 3p12 (rs2660753: P =
0.037).
Discussion
In this study, we examined PCa risk-related loci that were identified in previous GWAS
using a family-based association approach based on 1,979 HPC families of Caucasian
descent collected by the ICPCG. Family-based association methods evaluate whether
particular alleles are transmitted from parents to affected offspring in a proportion that is
different from that expected under the null hypothesis of no association between marker and
disease (Lunetta et al. 2000). Among 17 loci analyzed in this study, risk alleles of eight loci
were observed to be significantly over-transmitted from parents to affected offspring.
Because family-based studies utilize non-transmitted alleles from the same parents as the
control, these methods are not susceptible to population stratification. Therefore, the results
from our study provide more compelling evidence that these eight loci are truly associated
with risk of PCa. This study also demonstrates that typically low penetrance variants
identified from GWAS studies are also important for PCa in HPC families.
Family-based studies may be ideal for validating previously identified genetic risk factors
from case–control studies by the absence of susceptibility to false-positive results due to
population stratification. GWAS studies generally identify common variants of
comparatively lower penetrance, while linkage-based family studies identify rare highly
penetrant variants. The nine loci associations that were not replicated in this FBAT analysis
may simply represent variants of low penetrance. Our study also does not distinguish which
of several possible mutations may be causative. Therefore, there may exist mutations in a
gene that are weakly penetrant, and that identify a given locus in a GWAS, while a few rare
and highly penetrant mutations, such as loss-of-function mutations, segregate in a subset of
families and lead to validation in the FBAT analysis. These approaches are also efficient
when utilizing the large family-based samples that have been collected in the past for
genetic linkage studies. In the present study, 1,979 families with a total of 5,730 affected
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members collected from 12 groups in the ICPCG were analyzed. However, the diminished
statistical power resulting from the matching of transmitted with non-transmitted alleles
from the same family is a limitation of this approach (Lange et al. 2008). We cannot
formally exclude the possibility that the remaining nine loci, which were originally
associated with PCa risk in case–control studies (Amundadottir et al. 2006; Duggan et al.
2007; Eeles et al. 2008; Gudmundsson et al. 2007a, b; Thomas et al. 2008; Yeager et al.
2007), and for which significant differences between observed and expected allele
transmissions were not observed in the current FBAT analyses, were not associated with
disease risk in HPC families.
In addition to the validation of findings reported in previous studies, this study provides
another level of confirmatory evidence supporting the importance of genetic risk factors in
HPC. A GWAS performed by Eeles et al. (2008) using familial or early onset cases reported
that genetic variants at 3p12, 6q25, 7q21, 8q24 region 1, region 2 and region 3, 10q11,
11q13, 17q12, 17q24, 19q13 and Xp11 were observed to have genome-wide significant
associations with PCa risk, suggesting that these loci may account for some portion of the
heritability in families with excess PCa. Our study confirms a role of loci at 8q24 region 1,
region 2 and region 3, 10q11, 11q13, 17q12, 17q24, and Xp11, but not at 3p12, 6q25, 7q21
and 19q13.
We further focused on families with larger numbers of affected men as well as those with
early onset PCa cases and found three and six loci with significant associations, respectively.
Generally, families with such characteristics may be more likely to reflect an important role
for genetic factors in disease etiology. However in this study, we noted that some significant
loci were not involved in the larger or early onset families. This is not surprising, as GWAS
are not aimed at identifying rare highly penetrant loci that would be expected to characterize
such families. Thus, these loci may not contribute to the heritability of multiple or early
onset PCa. Alternatively, our results may reflect limitations in statistical power associated
with the data set. Therefore, we propose that the results based on significantly over-
transmitted risk alleles in multiple or early onset families, but not all families, should be
interpreted with caution.
Amundadottir et al. (2006) originally identified genetic variants at 8q24 to be associated
with PCa risk using a genome-wide linkage scan in 323 extended PCa families followed by
two case–control groups of European ancestry and one African American group. Subsequent
studies have consistently confirmed these findings and suggested at least three distinct
regions within 8q24 that are independently associated with PCa risk (i.e., regions 1, 2 and 3,
Table 2) (Gudmundsson et al. 2007a; Haiman et al. 2007; Yeager et al. 2007). In the current
study, we genotyped three to four SNPs at each region, and found a significant association
for at least one SNP in each locus. Interestingly, the SNP rs16901979 at 8q24 region 2 was
also significantly associated with PCa risk in families with five or more affected men, or
those with an average age at diagnosis of 65 years or less. These results suggest that genetic
variants at three independent regions of 8q24 are all implicated in the inherited risk of PCa
in HPC families.
Our study has strengths and limitations. The family-based association design is a strength,
offering the ability to reduce the risk of false-positive findings due to population
stratification. Another strength is the large number of HPC families included in the analyses
that yielded a measure of statistical power that reduces the inefficiency of family-based
association studies when considering the matching of transmitted with non-transmitted
alleles in the same family. A limitation is the potential for heterogeneous genetic and
environmental influences in PCa families collected from multiple locations across the US
and Europe.
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In summary, we confirmed multiple PCa risk-associated loci identified in GWAS or follow-
up studies using a family-based association design. Our results suggest that these regions
associated with sporadic PCa risk are not due to population stratification or admixture, and
may account for a proportion of the inherited risk associated with HPC families. Finally, this
study demonstrates the value of utilizing existing familial samples, originally collected for
the purpose of linkage, to identify findings from a GWAS that are relevant for a disease in
high-risk families.
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